Objective-To identify any excess mortality caused by adjuvant radiotherapy for early breast cancer.
Design-Prospective randomised clinical trial. Two thousand subjects needed for study to Interventions-One group of women (n=1376) had simple mastectomy followed by immediate postoperative radiotherapy (1320 to 1510 rets). The remaining women (n= 1424) had simple mastectomy with subsequent careful observation of the axilla, radiotherapy being delayed until there was obvious progression or recurrence of disease locally.
Endpoint-Increased mortality in patients treated with radiotherapy from causes other than breast cancer.
Measurements and main results -Survival was measured from time of first treatment to death or last follow up. Deaths from any cause and from specified causes were counted as events. Comparison over the whole follow up showed a slight excess mortality in the group treated with radiotherapy (relative risk 1-04; 95% confidence interval 0-94 to 1-15). The relative risk of death from breast cancer was 0 97 (0.87 to 1-08) but that of death from other causes was 1-37 (1-09 to 1.72), the increase mainly being in women who had had tumours of the left breast (161 (1.17 to 2.24)) and had been treated with orthovoltage (1.85 (1-27 to 2-71)). Analysis of causes of death after five years showed a relative risk of 2*11
(1-25 to 3.59) for new malignancies and of 1-65 (1-05 to 2.58) for cardiac disease, the increase in cardiac mortality being most pronounced in patients who had had tumours of the left breast and whose treatment had included orthovoltage radiation (relative risk 2.67 (1-28 to 5 .55)).
Conclusions-Adjuvant radiotherapy after simple mastectomy for early breast cancer produces a small excess late mortality from other cancers and cardiac disease. The risk has to be balanced against the higher risk of local recurrence when immediate postoperative radiotherapy is not given. The balance has to be assessed for each patient, and for many patients radiotherapy will still be desirable in the initial treatment of their early breast cancer.
Introduction
Postoperative radiotherapy reduces the rate of local recurrence after treatment for early breast cancer.' 2 No significant improvement in rates of survival has been shown after radiotherapy, and some critics have claimed that it has a deleterious effect. ' Causes of death were determined from information given on the death report form, copies of death certificates, and, in some cases, correspondence with treating clinicians and examination of the patient's notes. Deaths were first classified as due or not due to breast cancer. Deaths not due to breast cancer were then subdivided into deaths from other malignant disease; deaths related to cardiac disease -that is, heart failure, myocardial infarct, coronary thrombosis; and deaths from all other causes. Included in this last group were all cardiovascular deaths not recorded in the second group. A few patients could not be classified, and for some others there was considerable uncertainty about the correct classification.
Statistical comparisons between the two groups were made with logrank tests,6 counting as events all deaths or one particular classification of death-for example, deaths due to breast cancer and deaths related to cardiac disease.
Results Figure 1 shows the survival curves in the two groups over the 18 years of follow up. (fig 2) , however, the curves began to separate in the second quinquennium, and, over the whole period of follow up mortality from these causes was significantly higher in the group treated with radiotherapy (relative risk 1- treated with orthovoltage was also significant (p= 0.03).
As the excess deaths in patients with tumours of the left breast may have been due to irradiation of the heart region, and especially as orthovoltage, with its more lateral scatter, gives a higher dose of radiation to this region, we examined in more detail the deaths due to causes other than breast cancer after five years, when (fig 2) . Table II shows the breakdown by cause of death after five years in the two groups of the trial. More deaths related to cardiac disease and other malignancies were seen in the group treated with radiotherapy. The increased deaths from other malignancies in the patients treated with radiotherapy followed an increased incidence of new malignancies (table IV) . There were also more new malignancies in the opposite breast, which were not allowed for in any of the analyses of cause of death as determining whether deaths from breast cancer were due to the first or second primary was impossible. These findings lend some support to the suggestion that radiotherapy may adversely affect the immune system.' In previous studies of the excess risk of cancer associated with radiotherapy the malignancies were predominantly in or close to the parts of the body that received the highest radiation. Thus, for example, patients irradiated for ankylosing spondylitis or an artificial menopause showed the excess of malignancies after long follow up predominantly in the heavily irradiated sites.7-9 The fact that the excess malignancies in our study were not predominantly in or close to the parts of the body that would have received the highest dose of radiation, however, might indicate that the long term adverse systemic effect is mediated by irradiation of the lymphocytes recirculating in the thoracic duct. Our results are also at variance with those of Jones and Ribeiro, who did not find a significant excess of deaths from other cancers in the patients treated with radiotherapy in trials in Manchester in 1949-55.'°T he other main contribution to the excess mortality in the group treated with radiotherapy was from deaths related to cardiac disease in patients who had had tumours of the left breast (table III) . This would be consistent with radiation damaging the heart and its associated structures. Irradiation of the heart would arise mainly from the tangential pectoral fields used in the usual postoperative technique, and because of increased sideways scatter the dose would be higher with orthovoltage than with supervoltage radiation. The fact that the excess mortality seems to have been mainly in patients who had had tumours of the left breast treated by orthovoltage radiation supports this hypothesis. Caution is needed, however, in interpreting these analyses of subgroups and the hypotheses derived from the data: the observation concerning orthovoltage radiotherapy (which was not a randomised option) may be a statistical artefact. Nevertheless, the same tendency for more deaths due to cardiac disease in patients who had had tumours of the left breast was reported in the Manchester trials, in which orthovoltage was used, though a test for interaction between tumours of the left and right breasts was not significant. ' What are the implications of our results for the current use of adjuvant radiotherapy to treat early breast cancer? As always, the harmful effects of treatment have to be weighed against its benefits. Radiotherapy reduces the risk of local recurrence and the consequent distress this may cause a patient due to uncontrolled local disease at the time of death." It may also be considered an essential part of any treatment aimed at conserving the breast, an option that many patients consider highly desirable. On the debit side are the immediate trauma and inconvenience caused by radiotherapy, and to these must now be added the increased risk of death after long follow up.
The risk of death, however, must be put in perspective. The number ofexcess deaths is small in relation to the total number of patients treated. In the total follow up period (to 1988) We thank all who took part in this trial; Mrs J Reeley for typing the manuscript; and the Cancer Research Campaign for the continued financial support.
